An Open-Label, Dose-Response Study of CM4620 Injectable Emulsion (CM4620-IE) in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS)
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs CM 4620 (Primary)
- Indications Pancreatitis
- Focus Adverse reactions
- Sponsors CalciMedica
- 01 Aug 2018 Accordign to a CalciMedica media release, the first patients in this study have been dosed.
- 11 Apr 2018 Status changed from not yet recruiting to recruiting.
- 17 Jan 2018 Status changed from planning to not yet recruiting.